Promising combo trial for lymphoma halted early

NCT ID NCT03983668

Terminated Disease control Sponsor: Umar Farooq Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a combination of two immune-boosting drugs—pembrolizumab (Keytruda) and CMP-001—in 14 adults with lymphomas that had come back or stopped responding to treatment. The goal was to find a safe dose that could shrink tumors. However, the study was terminated before completion, so we do not know if the combination works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) and CMP-001 (an immune-stimulating drug)
What this could lead to: If it had worked, this combination might have offered a new treatment option for people with lymphomas that did not respond to standard therapy.
What could go wrong: The trial was terminated early with only 14 participants, so we have no clear evidence it works. Early-stage cancer trials often fail to show benefit or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.